Ann: Stable Cell Line for Production of PAT-DX3 Established, page-13

A couple of money shot bullet points from the Ann

"significantly ahead of schedule"

""In view of this potential, the Company is actively exploring partnering opportunities for PAT-DX3 to be used in antibody drug conjugates (ADCs) for the targeted intracellular delivery of cancer drugs and a range of other payloads such as nucleic acids.""

"" There is a lot of interest in PAT-DX3 both as a therapeutic agent in its own right and for the intracellular delivery of therapeutic payloads into brain and other cells. With this key reagent now identified and in hand, we can rapidly move into developing a commercial-scale production process to support both the clinical and partnering opportunities we have for PAT-DX3.""

Anyone think that the Dr has already narrowed down his "PREFFERED PARTNER"" for taking DX-3 to trial?

I think just one or two more ticks and the offers are starting to be made public and just not behind closed doors and that is really when you want to be in as that could be a multi=bagging Ann on its own..